Anthera Pharma Q1 net loss widens
The company’s loss from operations was $18.67m, compared to $6.47m for the same period last year. Total operating expenses for the first quarter ended 31 March 2011 were
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.